Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk - a knol by Christine M. Nguyen

Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk


Azathioprine (AZA), 6-mercaptopurine (6-MP), and thioguanine (TG) are thiopurine drugs. These agents are indicated for the treatment of various diseases including hematologic malignancies, inflammatory bowel disease (IBD), rheumatoid arthritis, and as immunosuppressants in solid organ transplants. Thiopurine drugs are metabolized, in part, by thiopurine methyltransferase (TPMT). TPMT displays genetic polymorphism resulting in null or decreased enzyme activity. At least 20 polymorphisms have been identified, of which, TPMT *2, *3A, *3B, *3C, and *4 are the most commonly studied. These polymorphisms have been associated with increased myelosuppression risk. TPMT genotyping may be useful to predict this risk.

Contents
◦Clinical Scenario
◦Test Description
◦Public Health Importance
◦Published Reviews, Recommendations and Guidelines
◦Evidence Overview
◦Links
◦Funding information
◦Competing interests

open here please:
Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk - a knol by Christine M. Nguyen